Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

the standard of care. The study found:

-- Up to 81 percent of those patients treated with R1626 1500 mg (twice-

daily) + PEGASYS + COPEGUS had an undetectable HCV viral load by week

four (mean reduction of 5.2 log10 IU/mL)

-- ALT, a liver enzyme, normalized in approximately 50 percent of patients

in R1626 treatment groups

-- Most reported adverse events were mild to moderate. Dose dependent,

reversible grade four neutropenia was observed in the R1626 arms (36

percent in patients receiving R1626 1500 mg + PEGASYS + COPEGUS), and

was the main reason for dose reduction and discontinuation

Lack of Resistance

According to a second presentation at the conference, resistance to R1626 was not identified following intensive testing for either two weeks of treatment with R1626 as monotherapy, or in patients treated with R1626 for four weeks in combination with the standard of care. These findings suggest that there is a high barrier to the development of resistance to R1626 in vivo.

Start of Phase IIb Trial

R1626 is being progressed into Phase IIb study, called POLI 1, to further investigate the new treatment regimens of R1626, in combination with standard or lower dose of PEGASYS and standard dose of COPEGUS. This Phase IIb trial is now open and enrolling patients in eight countries, including the United States. More information about R1626 and the clinical studies can be found on http://www.roche-trials.com.

"As a clinician, I am excited by the high rates of viral negativity that were observed after four weeks of treatment with R1626 in combination with the standard of care. The design of the Phase IIb study should enable us to find the doses of R1626, PEGASYS and COPEGUS that achieve the appropriate balance between safety and efficacy," said Dr. David Nelson, Director of Hepatology and Liver Transplantation at the
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 ... the addition of the "Market Assessment of ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... the respiratory imaging diagnostics market in ... Europe . The service provides detailed analysis ...
(Date:5/21/2015)... , May 21, 2015  (MUSE Booth ... Electronic Health Record (EHR) is invaluable in any ... EHRs are now a requirement and mainstream in ... continuously into the EHR is gaining traction in ... William Holmes, RN, Site Project Manager & Clinical ...
(Date:5/21/2015)... & Struggles (Nasdaq: HSII ), the premier provider ... and culture shaping worldwide, strengthens its healthcare ... addition of Tim Dietlin to the firm,s ... Dietlin has extensive life sciences and professional services experience ... Commercial functions to increase productivity, drive transformational change, and ...
Breaking Medicine Technology:United States and Europe Respiratory Diagnostics Market Assessment 2015 2Hospital Streamlines ICU Efficiency with Timely Data Integration 2Hospital Streamlines ICU Efficiency with Timely Data Integration 3Heidrick Increases Healthcare and Life Sciences Expertise 2
... , ST. LOUIS , Jan. 27 ... received Section 510 (k) clearance from the U.S. Food and ... first ophthalmic device linking patients and doctors between eye exams ... a frequent but brief exam on their ForeseeHome AMD Monitor, ...
... 27 Warner Chilcott plc (Nasdaq: WCRX ... from the U.S. Food and Drug Administration (FDA) to its New ... dose" oral contraceptive (also referred to as WC 3016).   , ... substance manufacturing facility and control testing laboratory used to support the ...
Cached Medicine Technology:Notal Vision's ForeseeHome(TM) AMD Monitor Receives FDA Clearance 2FDA Issues Complete Response Letter for Low Dose Oral Contraceptive 2FDA Issues Complete Response Letter for Low Dose Oral Contraceptive 3
(Date:5/22/2015)... 2015 Memorial Day weekend is typically considered ... is offering some tips to help promote safe travel. , ... be 383 traffic fatalities this Memorial Day weekend. Amica is ... Traffic Safety Association: , , Always ... wearing a seatbelt, whether they’re driving or riding along as ...
(Date:5/22/2015)... ZH Healthcare (ZH), a ... that Bill Lane, joins ZH’s Advisory Board. ... first of its kind, Freemium SaaS, Electronic Health ... Records (EHR) with an integrated practice management system ... portal, and more. Combined with its Revenue Cycle ...
(Date:5/22/2015)... NY (PRWEB) May 22, 2015 Medivo, Inc., ... “Positivity Rates and Genotype Results in ‘Baby Boomers’ Screened ... from a Nationwide Lab Test Database” at Digestive Disease Week, ... Medivo’s Clinical Affairs and Analytics team members Carol Smyth, MB; ... and Andrea Parker, MSI, along with Nancy Reau, MD from ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 DMG Productions ... Jr., scheduled to broadcast on Friday, May 29, 2015 ... Discovery Channel. , In this episode Innovations will explore ... back to business quickly through disaster recovery and restoration. ... company that works collaboratively to develop and deliver training ...
(Date:5/22/2015)... In April 2006, Veatch Consulting opened for ... they have concentrated their focus to working with over ... of this growth and their goals to better serve ... Colorado, Cleveland, Ohio, Houston, Texas and now Dallas, Texas. ... offices, dental start ups, orthodontic practices, pediatric dental practices, ...
Breaking Medicine News(10 mins):Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2
... Oxford, April 5, 2012 Elsevier, a world-leading ... and services, announces the Label-Free Technologies Conference to ... 2012. Organized by Elsevier in association with ... conference entirely dedicated to bringing together the latest ...
... 2012) - Men experience a marked drop in their testosterone ... type of lung cancer. That,s according to a University of ... Cancer, the official journal of the American Cancer ... hormone levels in men with anaplastic lymphoma kinase (ALK) positive ...
... HealthDay Reporter , WEDNESDAY, April 4 (HealthDay News) ... being passed through generations, could play an important role ... Three research teams sequenced the genes of children with ... families, and compared the sequences with those of their ...
... engineers and physicians from Brigham and Women,s Hospital ... (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, ... Karmanos Cancer Institute, and Weill Cornell Medical College ... cancer drug called BIND-014 in treating solid tumors. ...
... Simon Fraser University, has made a discovery that will change ... treated. The journal Nature has just ... and mutational evolution spectrum of primary triple negative breast cancers. ... what were thought to be triple negative breast cancer tumours. ...
... The incidence of head and neck cancers related to the ... the greatest increase among middle-aged white men, a new study ... for head and neck cancers, but the sexually transmitted infection ... to researchers from the Louisiana State University Health Sciences Center ...
Cached Medicine News:Health News:Clinical insight improves treatment with new lung cancer drug 2Health News:Clinical insight improves treatment with new lung cancer drug 3Health News:Researchers Find Gene Mutations That May Be a Key to Autism 2Health News:Researchers Find Gene Mutations That May Be a Key to Autism 3Health News:Researchers Find Gene Mutations That May Be a Key to Autism 4Health News:First targeted nanomedicine to enter human clinical studies 2Health News:First targeted nanomedicine to enter human clinical studies 3Health News:First targeted nanomedicine to enter human clinical studies 4Health News:Scientists uncover multiple faces of deadly breast cancer 2Health News:HPV-Related Head, Neck Cancers on the Rise 2
... ,Launched in 1988, this design revolutionized ... standard practice in general anesthesia. Used successfully ... Classic™ is a safe hands free alternative ... Classic™ can be used for a wide ...
... The Intubating LMA™ Airway. , ... or unexpected difficult airway, the LMA Fastrach™ ... without moving the head or neck. The ... attempts. , ,Selected by emergency teams ...
... an advancement in supralaryngeal airway management., ,The ... in the hypopharynx where it abuts the structure ... Cobra head design of the distal end of ... the epiglottis out of the way, facilitating ventilation ...
... superior, disposable supraglottic airway tool that utilizes ... design to provide the best non-intubating airway ... a safe, reliable, cost effective and efficient ... laryngoscopy is not feasible or attainable. With ...
Medicine Products: